Biorbis

A protein therapeutics event different to any before it.

Dr Thomas Kost Director, Biological Reagents and Assay Development GlaxoSmithKline	Dr Michael Doyle Group Leader, Protein Therapeutics Bristol-Myers Squibb Research and Development	Dr Chichi Huang Research Fellow Centocor (Johnson & Johnson)
Dr Andy Nixon Vice President, Lead Discovery and Biochemistry Dyax Corp	Dr Trevor Wilkinson Associate Director of Protein Sciences MedImmune	Prof Arne Skerra Professor of Biological Chemistry Technische Universitat Munchen
Dr Lars Abrahmsen Chief Scientific Officer Affibody	Dr Julian Bertschinger Co-founder and Chief Executive Officer Covagen	Dr Arnd Steuernagel Chief Scientific Officer ScilProtein
Dr Christina Furebring Vice President Research & Development Alligator Bioscience	Professor Christian Heinis Group Head EPFL	Dr Andreas Hohlbaum Chief Technology Officer Pieris AG
Dr Dominik Escher Managing Director and Vice President R&D ESBATech	Dr Antonio Maschio Partner Edwards Angell Palmer & Dodge Innovations LLP	Cecil Nick Vice President (Biotechnology) PAREXEL Consulting, UK
Dr Scott Glaser Director of Antibody Therapeutics Biogen Idec	Dr Kendall Mohler Senior Vice President, Research & Development Trubion	Dr Jeffrey Cleland Chief Executive Officer Versartis
		Dr Lutz Jermutus Senior Director, Technology MedImmune
Dr Josi Holz Chief Medical Officer Ablynx	Dr Karyn O'Neil Chief Scientific Officer, Centyrex Johnson & Johnson Ventures
Dr Graham Molineux, Executive Director, Research, Amgen Dr Samantha Cobb, Chief Executive Officer, AdAlta Dr Nico Mertens, Senior Director of Antibody Engineering, Biotecnol Dr Kevin FitzGerald, Chief Executive Officer, f-star GmbH

Stripped of tired case studies and presentations on the latest company share price, the Biorbis Advancing Protein Therapeutics event will focus on robust science, and address high opportunity areas and challenges around developing better protein drugs.

Designed by the likes of MedImmune, Amgen, Johnson & Johnson, Biogen Idec, GlaxoSmithKline, Bristol-Myers Squibb and a host of other leading big pharma and innovative biotechs, Advancing Protein Therapeutics will address a number of key areas with a frankness and sincerity that you won't find elsewhere.

What's on the Agenda?

The key areas being addressed focus on;

Improving the PK/PD of Protein Therapeutics through Effective Protein Engineering

Looking specifically at PEGylation, binding serum proteins, PASylation and Fc-fusions to improve therapeutics characteristics.

Producing Proteins for use in Therapeutic Applications

Novel gene expression techniques examining aspects of transient production in mammalian cells, chemical synthesis of peptides and viral gene delivery systems.

Optimising Efficacy, Minimizing Compromise

Examining novel formatting options in the development of protein therapeutics as well as developing alternative delivery methods.

Expanding the Alternative Scaffold Portfolio

Describing the challenges and applications of fc-fusion proteins and alternative antibody formats.

Advancing Multivalent Protein Therapeutics

Explore the benefits of bispecific antibodies and trispecific protein drugs

Targeting Less Accessible Antigens

See how GPCRs and ion channels are being developed as targets for biologics and how alternative scaffolds are targeting the area's antibodies can't go.

Enhancing Drug-like Qualities

Removing immunogenic moieties and developing formatting flexibility.

Why attend?

• Meet innovative scientists and research leaders from big pharma, large biotech and smaller innovative biotechs, and understand how they are meeting the challenges associated with developing more effective protein therapeutics.
• Leave the meeting with a surplus of new ideas and contacts to take back to your organization.
• The Biorbis Advancing Protein Therapeutics meeting focuses on delivering practical value, accelerating the field and helping to grow your business and/or research...

Background

The use of protein therapeutics has increased dramatically over the last ten to twenty years, but their role in medicine is still only in its infancy. There are so many opportunities within this field to enhance drug performance, overcome previously insurmountable hurdles and deliver better drugs to patients in a host of different therapeutic areas.

Advancing Protein Therapeutics focuses on exploiting new technologies, methodologies and know-how from within big pharma and biotech organisations to bring innovative new protein therapeutics to patients.